Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

AtLaS-M Study Group

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial'. Together they form a unique fingerprint.

Medicine & Life Sciences